Hanyang Med Rev.  2016 Nov;36(4):262-268. 10.7599/hmr.2016.36.4.262.

Risk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in South Korea

• Yang JH
• Park HO
• Byun JH
• Kim SH
• Moon SH
• Kim JD
• Kim DY

• KMID: 2361202
• DOI: http://doi.org/10.7599/hmr.2016.36.4.262

Abstract

BACKGROUND/AIMS
Multidrug-resistant tuberculosis (MDR-TB) is an important public health problem in South Korea. MDR-TB is difficult to control, and treatment is less effective than for drug-sensitive tuberculosis. The aim of this report is to determine the risk factors for poor outcomes for MDR-TB.
METHODS
We retrospectively and consecutively analyzed the clinical outcomes of MDR-TB patients registered at a single tuberculosis-specialized hospital in South Korea from January 2005 to February 2011. We used standard treatment outcome definitions for MDR-TB and used the combination of "defaulted", "treatment failed", and "died" as a composite poor outcome variable. We analyzed the risk factors associated with poor outcome.
RESULTS
Among the 258 patients sampled, 91 (35.3%) had MDR-TB on their first tuberculosis infection, while 167 patients (64.7%) who had previously been treated for tuberculosis had MDR-TB over the study period. Treatment outcomes revealed that 207 patients (80.2%) were cured of their infection, 15 (5.8%) completed their treatment, one (0.4%) defaulted treatment, 6 (2.3%) died, and treatment failed for 29 patients (11.3%). Multivariate Cox proportional-hazards regression analysis found that poor outcome were associated with a body mass index <18.5 kg/m2 (hazard ratio [HR]: 2.57; 95% confidence interval [CI]: 1.28-5.15, p = 0.008), being susceptible to four or fewer drugs at the start of treatment (HR: 3.89; 95% CI: 1.38-10.96, p = 0.01), and ofloxacin resistance (HR: 2.49; 95% CI: 1.06-5.81, p = 0.035).
CONCLUSIONS
Being underweight, susceptibility to four or fewer drugs, and ofloxacin resistance are independent prognostic factors of poor outcome for MDR-TB patients.

Keyword

Tuberculosis; Multidrug-resistant tuberculosis; Risk factors; fluoroquinolone

MeSH Terms

Body Mass Index
Humans
Korea*
Ofloxacin
Public Health
Retrospective Studies
Risk Factors*
Thinness
Treatment Outcome
Tuberculosis
Tuberculosis, Multidrug-Resistant*
Ofloxacin

Reference

1. World Health Organization. Global tuberculosis report 2015. WHO/HTM/TB 2015.10. Geneva: World Health Organization;2015.

2. Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee HY, et al. Extensively Drugs-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital. Clin Infect Dis. 2008; 46:42–49.

3. Annual report on the notified tuberculosis patients in Korea. Seoul, South Korea: Korean Center for Disease control and Prevention Korean institute for Tuberculosis;2005.

4. Hong YP, Kim SJ, Lew WJ, Lee SH, Lee EK. Cohort analyses of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983-1994. Int J Tuberc Lung Dis. 1998; 2:365–371.

5. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis. 2003; 7:912–919.

6. Park WS, Kang HY, Kim SJ, Cha JO, Son HJ, Park O. Notified tuberculosis status in Korea, 2015. Public Health Weekly Report, KCD. 2015; 9(19):342–345.

7. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. WHO/HTM/TB/2013.2. Geneva: World Health Organization;2013.

8. Leimane V, Riekstina V, Holtz TH, Skripconoka V, Thorpe LE, Laserson KF. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005; 365:318–326.

9. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ. Treatment outcomes for HIV-Unifected Patients with Multidurg-Resistant and Extensively Drug-Resistant. Tuberculosis – Clin Infect Dis. 2008; 47:496–502.

10. Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. Int J Tuberc Lung Dis. 2014; 18(5):564–570.

11. Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to firs- and second-line drugs: An individual patient data Meta-analysis. Clin Infect Dis. 2014; 59(10):1364–1374.

12. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN. Multidurg resistant pulmonary tucerculosis treatment regimens and patient outcomes: An individual patient data Meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.

13. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis. 1985; 131:348–351.

14. Willcox PA, Groenewald PJ, Mackenizie CR. Ofloxacin-based chemotherapy in multiply durg-resistant pulmonary tuberculosis. Drugs. 1993; 45:suppl 3. S223–S224.

15. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000; 117:744–751.

16. Leimane V, Dracniece G, Riekstina V, Sture I, Kammerer S, Chen MP. Treatment oucome of multidrug/extensicely drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J. 2010; 36(3):584–593.

17. Schwenk A, Hodson L, Wright A, Ward LC, Rayner CF, Grubnic S. Nutrient partitioning during treatment of tuberculosis: gain in body fat mass but not in protein mass. Am J Clin Nutr. 2004; 79:1006–1012.

18. Jo KW, Lee SD, Kim WS, Kim DS, Shim TS. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2014; 18(1):39–43.

19. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006; 61:158–163.

20. Pablos-Mendez A, Rabiglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance. N Engl J Med. 1998; 338(23):1641–1649.